Eli Lilly And Co (LLY) Shares Bought by JNBA Financial Advisors

JNBA Financial Advisors raised its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 157.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,800 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. JNBA Financial Advisors’ holdings in Eli Lilly And Co were worth $193,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Morgan Stanley raised its holdings in shares of Eli Lilly And Co by 37.8% in the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after acquiring an additional 1,227,888 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Eli Lilly And Co by 1.3% in the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock valued at $5,686,808,000 after acquiring an additional 864,451 shares in the last quarter. Investec Asset Management LTD raised its holdings in shares of Eli Lilly And Co by 49.6% in the second quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock valued at $215,738,000 after acquiring an additional 838,271 shares in the last quarter. Smith Asset Management Group LP bought a new stake in shares of Eli Lilly And Co in the second quarter valued at about $65,407,000. Finally, Unigestion Holding SA bought a new stake in shares of Eli Lilly And Co in the second quarter valued at about $64,279,000. Institutional investors and hedge funds own 76.36% of the company’s stock.

In other news, major shareholder Eli & Co Lilly sold 4,531 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $14.33, for a total transaction of $64,929.23. Following the sale, the insider now owns 3,934,137 shares in the company, valued at $56,376,183.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of the business’s stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the sale, the insider now owns 119,191,172 shares in the company, valued at approximately $13,815,448,746.52. The disclosure for this sale can be found here. Insiders sold 1,380,271 shares of company stock worth $143,763,002 in the last quarter. 0.11% of the stock is owned by insiders.

LLY has been the subject of several recent research reports. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, July 9th. Credit Suisse Group set a $84.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a report on Friday, July 13th. Jefferies Financial Group set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Sunday, July 15th. Bank of America lifted their price objective on Eli Lilly And Co from $86.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, July 17th. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Wednesday, July 18th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $111.53.

LLY opened at $106.75 on Friday. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The stock has a market capitalization of $114.65 billion, a price-to-earnings ratio of 21.22, a P/E/G ratio of 1.73 and a beta of 0.29.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a $0.5625 dividend. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 2.11%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What is a conference call?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply